Small Molecule vs ADC — Oncology Deal Terms Comparison

Small Molecule Median Upfront

$258M

Total: $1.6B

ADC Median Upfront

$411M

Total: $2.6B

Small Molecule Royalties

11.8%-19.3%

Tiered to 23.3%

ADC Royalties

13.6%-22.2%

Tiered to 26.2%

Model Your Deal

Market Analysis

In oncology, Small Molecule and ADC represent two of the most actively transacted modalities. At Phase 2, Small Molecule deals carry a median total deal value of $1.6B with $258M upfront, compared to $2.6B total value and $411M upfront for ADC. The valuation difference reflects distinct risk-reward profiles, manufacturing complexity, and competitive dynamics.

Milestone structures diverge between the two modalities. Small Molecule development milestones average $345M versus $550M for ADC. Commercial milestones are $483M for Small Molecule and $770M for ADC. Royalty rates range from 11.8%-19.3% for Small Molecule and 13.6%-22.2% for ADC.

Customize these benchmarks for your asset

Adjust phase, modality, competitive position, and 10+ other parameters.

Open Calculator

Frequently Asked Questions

How do Small Molecule and ADC deal terms compare in oncology?

Small Molecule Phase 2 deals average $1.6B total deal value ($258M upfront), while ADC deals average $2.6B ($411M upfront). The difference reflects modality-specific risk profiles, manufacturing considerations, and competitive positioning.

Which modality commands higher royalty rates: Small Molecule or ADC?

Small Molecule base royalties range from 11.8% to 19.3%, while ADC royalties range from 13.6% to 22.2%. High-tier escalation reaches 23.3% for Small Molecule and 26.2% for ADC.

How do milestone structures differ between Small Molecule and ADC?

Small Molecule deals allocate $345M to development milestones vs $550M for ADC. Commercial milestones are $483M (Small Molecule) vs $770M (ADC), reflecting different commercialization profiles and market expectations.

PRO

Full Benchmark Analysis

Complete deal term ranges, comparable transactions, and negotiation insights.

Start 7-Day Free Trial

$299/mo after trial · Cancel anytime

Related Benchmarks

Ready to Calculate Your Deal Terms?

Get instant, customized benchmarks based on real market data from 1,600+ biopharma licensing deals.

Start Calculating

For Funds & Advisors

Need the full deal landscape?

The Deal Intelligence Brief covers every modality and deal structure for this indication — 52 deal calculations, AI strategic narrative, comparable transactions, partner matching, and white-label branding. Delivered in 24 hours.

Configure Brief — $2,500All-inclusive · White-label · Walkthrough included